EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical features, MRI , molecular alternations, and prognosis of astrocytoma based on WHO 2021 classification of central nervous system tumors: A single‐center retrospective study

Yuekun Wang, Hao Xing, Xiaopeng Guo, Wenlin Chen, Yaning Wang iD, Tingyu Liang, Hai Wang, Yilin Li, Shanmu Jin, Yixin Shi, Delin Liu, Tianrui Yang und 10 weitere

Cancer Medicine · 2024

DOI: 10.1002/cam4.7369 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Yuekun Wang und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance, Peking Union Medical College Hospital, Chinese Academy o…. Hauptthemen laut MEDLINE: Astrocytoma, Magnetic Resonance Imaging, Neoplasm Grading, World Health Organization. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National High Level Hospital Clinical Research Funding, Tsinghua University-Peking Union Medical College Hospital Initiative Scientific Research Program, Beijing Municipal Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The diagnosis of glioma has advanced since the release of the WHO 2021 classification with more molecular alterations involved in the integrated diagnostic pathways. Our study aimed to present our experience with the clinical features and management of astrocytoma, IDH mutant based on the latest WHO classification.

Methods

Patients diagnosed with astrocytoma, IDH‐mutant based on the WHO 5th edition classification of CNS tumors at our center from January 2009 to January 2022 were included. Patients were divided into WHO 2–3 grade group and WHO 4 grade group. Integrate diagnoses were retrospectively confirmed according to WHO 2016 and 2021 classification. Clinical and MRI characteristics were reviewed, and survival analysis was performed.

Results

A total of 60 patients were enrolled. 21.67% (13/60) of all patients changed tumor grade from WHO 4th edition classification to WHO 5th edition. Of these, 21.43% (6/28) of grade II astrocytoma and 58.33% (7/12) of grade III astrocytoma according to WHO 4th edition classification changed to grade 4 according to WHO 5th edition classification. Sex ( p = 0.042), recurrent glioma ( p = 0.006), and Ki‐67 index ( p < 0.001) of pathological examination were statistically different in the WHO grade 2–3 group ( n = 27) and WHO grade 4 group ( n = 33). CDK6 ( p = 0.004), FGFR2 ( p = 0.003), and MYC ( p = 0.004) alterations showed an enrichment in the WHO grade 4 group. Patients with higher grade showed shorter mOS (mOS = 75.9 m, 53.6 m, 26.4 m for grade 2, 3, and 4, respectively, p = 0.01).

Conclusions

Patients diagnosed as WHO grade 4 according to the 5th edition WHO classification based on molecular alterations are more likely to have poorer prognosis. Therefore, treatment should be tailored to their individual needs. Further research is needed for the management of IDH‐mutant astrocytoma is needed in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AstrocytomaMagnetic Resonance ImagingNeoplasm GradingWorld Health OrganizationMutationHumansMaleFemaleRetrospective StudiesMiddle AgedAdultPrognosisIsocitrate DehydrogenaseCentral Nervous System NeoplasmsAgedYoung AdultBrain NeoplasmsAdolescent

Stichwörter der Autor:innen

FGFR2WHO classificationWHO grade 4 astrocytomaastrocytomaintegrate diagnoses

Substanzen

Isocitrate Dehydrogenase

Autor:innen und Institutionen

  • Department of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • China Anti-Cancer Association Specialty Committee of Glioma, Beijing, China.
  • '4+4' Medical Doctor Program, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Eight-year Medical Doctor Program, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Tsinghua University Ringgold standard institution School of Medicine, Tsinghua University, Beijing, China.

ORCID-Profile: Yaning Wang, Siying Guo, Yu Wang, Wenbin Ma

Förderung

  • National High Level Hospital Clinical Research Funding
  • Tsinghua University-Peking Union Medical College Hospital Initiative Scientific Research Program
  • Beijing Municipal Natural Science Foundation

Zitieren

APA

Wang, Y., Xing, H., Guo, X., Chen, W., Wang, Y., Liang, T., Wang, H., Li, Y., Jin, S., Shi, Y., Liu, D., Yang, T., Xia, Y., Li, J., Wu, J., Liu, Q., Qu, T., Guo, S., Li, H., …, & Ma, W. (2024). Clinical features, MRI , molecular alternations, and prognosis of astrocytoma based on WHO 2021 classification of central nervous system tumors: A single‐center retrospective study. Cancer Medicine. https://doi.org/10.1002/cam4.7369

Vancouver

Wang Y, Xing H, Guo X, Chen W, Wang Y, Liang T, et al. Clinical features, MRI , molecular alternations, and prognosis of astrocytoma based on WHO 2021 classification of central nervous system tumors: A single‐center retrospective study. Cancer Medicine. 2024. doi:10.1002/cam4.7369

BibTeX
@article{Wang2024,
  author = {Wang, Yuekun and Xing, Hao and Guo, Xiaopeng and Chen, Wenlin and Wang, Yaning and Liang, Tingyu and Wang, Hai and Li, Yilin and Jin, Shanmu and Shi, Yixin and Liu, Delin and Yang, Tianrui and Xia, Yu and Li, Junlin and Wu, Jiaming and Liu, Qianshu and Qu, Tian and Guo, Siying and Li, Huanzhang and Zhang, Kun and Wang, Yu and Ma, Wenbin},
  title = {Clinical features, MRI , molecular alternations, and prognosis of astrocytoma based on WHO 2021 classification of central nervous system tumors: A single‐center retrospective study},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.7369}
}
Kostenlos starten →